Swiss Diabetes Venture Fund

Swiss Diabetes Venture Fund focuses on addressing one of healthcare's most significant challenges: diabetes, which affects 1.3 billion people globally and requires constant management with no existing cure. The fund strategically invests in groundbreaking startups developing solutions for diabetes and its numerous complications, including significant associated conditions such as mental health issues, kidney disease, and wound care—each representing substantial therapeutic markets with significant innovation potential. By targeting these interconnected health challenges, the fund positions itself at the intersection of multiple high-growth healthcare segments ready for technological advancement.

What distinguishes this investment vehicle is its specialized knowledge ecosystem created through the strategic partnership between Serpentine Ventures and the Diabetes Center Berne (DCB). This collaboration creates an unparalleled support structure for portfolio companies, combining Serpentine's investment expertise with DCB's position as a global leader in diabetes technology innovation. Portfolio companies gain access to clinical expertise, regulatory guidance, and industry connections that accelerate their development timelines and enhance their market positioning in ways conventional investors cannot match.

The fund maintains a global investment scope, seeking exceptional entrepreneurial teams worldwide who are developing transformative technologies across the diabetes care spectrum. Investment interests span diagnostic innovations, treatment delivery systems, digital health platforms, AI-powered management tools, and novel therapeutic approaches addressing both diabetes itself and its complications. This comprehensive approach acknowledges the multifaceted nature of diabetes care and the necessity for innovation across the entire patient journey, from prevention and diagnosis to treatment and long-term management of complications.

Beyond capital deployment, the Swiss Diabetes Venture Fund provides portfolio companies with strategic advantages through its extensive healthcare network and deep domain expertise. Portfolio companies benefit from connections to leading diabetes researchers, clinicians, industry partners, and potential acquirers. The fund's specialized focus allows it to evaluate diabetes-related innovations with exceptional precision, identifying truly disruptive technologies with the potential to improve patient outcomes while creating significant value in a market characterized by high unmet needs and substantial healthcare expenditures. This combination of specialized focus, global reach, and strategic partnerships positions the fund as a catalyst for meaningful innovation in diabetes care.